About Nextech Invest
Nextech Invest is a private equity firm founded in 1998. It is primarily based in Zurich, Switzerland. In the last 12 months, it has participated in 6 funding rounds.
A lot of funds co-invest with Nextech Invest, with names like Casdin Capital sharing a substantial percentage of its portfolio.
Nextech Invest has a team of 31 people, including 17 partners.
Key Metrics
Nextech Invest's Portfolio
They have invested in a total of 78 companies. Their most recent investment was in Flare Therapeutics (Series C round) on Jun 30, 2026. Here is the most recent investment by Nextech Invest:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Jun 30, 2026 | Series C | 6485 | ||
Mar 31, 2026 | Series A | 5106 | ||
Jan 08, 2026 | Series F | 5880 | ||
Dec 21, 2025 | Series B | 1632 |
Here is the portfolio snapshot of Nextech Invest:
Investments by Year
The maximum number of investments were made in 2022
Team profile of Nextech Invest
Nextech Invest has a team of 31 members including 17 Partners and 4 Principals located in United States, Switzerland and 2 more locations. Nextech Invest's team sits on the board of 1 company.Here is a list of top team members in Nextech Invest:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Zurich | - | ||
Partner | Switzerland | - | ||
Partner | Johns Island | - | ||
Partner | Cambridge | - | ||
Partner | Switzerland | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | United States | - | - | |
Partner | - | - | - | |
Partner | Los Angeles | - | - |
Co-investors of Nextech Invest
Over the past 28 years, 143 investors have co-invested in Nextech Invest's portfolio companies.
- Top Co-investors of Nextech Invest: 143 investors entered a company along with Nextech Invest. These include investors like Casdin Capital (10 companies).
Nextech Invest News
•
Khartis Therapeutics Raises $50M in Series B FundingFinSMEs•Aug 13, 2026•Nextech Invest, Forge Life Science Partners, Alexandria, Longwood Fund and 1 other
•
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
Atavistik Bio Raises $120M in Series B FinancingFinSMEs•Dec 21, 2025•Nextech Invest, Lux Capital, Atavistik, Regeneron Ventures and 7 others
•
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)Business Wire•Oct 30, 2025•Ascenta Capital, Frazier Life Sciences, Fidelity Investments, Deep Track Capital and 13 others
•
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra TherapeuticsPR Newswire•Oct 22, 2025•Electra Therapeutics, EQT, Sanofi, Mubadala and 14 others
•
Tubulis Secures €308 Million to Advance Antibody-Drug Conjugate InnovationEU-Startups•Oct 15, 2025•Tubulis Technologies, Venrock, Ascenta Capital, Frazier Life Sciences and 12 others
•
AIRNA Hits $155M Series B Haul To Advance RNA Editor for Rare Genetic DiseaseBioSpace•Apr 01, 2025•AIRNA, Venrock, Forbion, RTW Investments and 2 others
•
Airna adds $155M in fundingBioPharmaDive•Apr 01, 2025•AIRNA, Venrock, Forbion, RTW Investments and 3 others
•
Radiopharma biotech Alpha-9 Oncology closes $175M Series C fundraiseEndPoints News•Oct 23, 2024•Alpha-9 Oncology, Janus Henderson Investors, Delos Capital, Digitalis Ventures and 12 others